ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.45
+1.41%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$8.68M
MomentumView details →
1D Return
+1.41%
YTD Return
−52.39%
RSI (14)
60.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$8.68M
RSI (14)
60.7
MomentumView details →
1D Return
+1.41%
YTD Return
−52.39%
SummaryUpdated Jun 1, 2026
Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a clinical-stage pharmaceutical company founded in 2018 and based in La Jolla, California. The company specializes in developing abuse-resistant and overdose-protection opioid medications to address the ongoing opioid crisis in the United States. Since going public in March 2018, Ensysce has focused on advancing its proprietary drug delivery platforms through clinical trials while generating revenue from licensing agreements and research collaborations.
Similar companies
Latest newsMore news →
Ensysce Biosciences announced completion of enrollment in the final stage of its PF614-MPAR-102 clinical study evaluating its MPAR overdose-protection technology.4d agoEnsysce Biosciences, Inc. announced a private placement financing.17d agoEnsysce Biosciences, Inc. announced the acquisition of Cy Biopharma.17d ago